Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide constructs for nasal administration

a polypeptide and construct technology, applied in the field of polypeptide constructs for nasal administration, can solve the problems of ineffective administration of conventional antibodies and their derived fragments or single-chain formats (e.g. scfv's), inability to administer conventional antibodies or their derived fragments or single-chain formats, and inability to treat, and prevent and/or relieve symptoms. , the effect of treating, preventing and/or alleviating the symptoms

Inactive Publication Date: 2009-12-31
ABLYNX NV
View PDF49 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a polypeptide construct that includes at least one single domain antibody directed against a target for treating, preventing, and / or alleviating disorders related to inflammatory processes. The polypeptide construct can be administered orally, nasally, through the vaginal and / or rectal tract, or through the skin. It can also be delivered to the tissues beneath the tongue, nasally, by inhalation, or topically. The polypeptide construct can be used to treat disorders that are susceptible to modulation by an anti-target therapeutic compound that is able pass through the gastric environment or the wall of the intestinal mucosa or nose, upper respiratory tract, or lung without being inactivated.

Problems solved by technology

However, they have one important drawback: these are complex, large molecules and therefore relatively unstable, and they are sensitive to breakdown by proteases.
Because the degradation they undergo during passage through, for instance, the gastrointestinal tract, administration of conventional antibodies and their derived fragments or single-chain formats (e.g. scFv's) is not very effective.
This means that conventional antibody drugs cannot be administered orally, sublingually, topically, nasally, vaginally, rectally or by inhalation because they are not resistant to the low pH at these sites, the action of proteases at these sites and in the blood and / or because of their large size.
Administration by injection is therefore the most frequently used method of administration although the method has many disadvantages, for example: (a) poor tolerance by patients, especially when treating chronic disorder; (b) a consequent risk of poor compliance with the dosage when the drug is not a ‘life saver’; (c) difficulty of carrying out self-administration by the patient; (d) possible non-availability of suitable surroundings for carrying out the procedure in an aseptic manner; (e) requires specialist training in order to use a hypodermic syringe or needle correctly and safely.
However, they have important drawbacks: these antibodies are complex, large molecules and therefore relatively unstable, and they are sensitive to breakdown by proteases.
Moreover, the domains of such antibodies are held together by disulphide bonds that dissociate in the reducing environment of the cytoplasm leading to a substantial loss of binding activity.
Therefore, they cannot be used to target intracellular proteins.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide constructs for nasal administration
  • Polypeptide constructs for nasal administration
  • Polypeptide constructs for nasal administration

Examples

Experimental program
Comparison scheme
Effect test

example 1

VHH Directed Against IgE

[0370]Two llama's were immunized with human IgE, Scripps laboratories, Cat nr. I0224. The following immunization schemes were used according to Table 1.

[0371]Different sources for RNA extraction were used:[0372]150 ml immune blood, between 4 and 10 days after the last antigen injection[0373]lymph node biopsy 4 days after the last antigen injection

[0374]Peripheral blood lymphocytes (PBLs) were isolated by centrifugation on a density gradient (Ficoll-Paque Plus Amersham Biosciences). PBLs and lymph node were used to extract total RNA (Chomczynski and Sacchi 1987). cDNA was prepared on 200 μg total RNA with MMLV Reverse Transcriptase (Gibco BRL) using oligo d(T) oligonucleotides (de Haard et al., 1999). The cDNA was purified with a phenol / chloroform extraction, followed by an ethanol precipitation and subsequently used as template to amplify the VHH repertoire.

[0375]In a first PCR, the repertoire of both conventional (1.6 kb) and heavy-chain (1.3 kb) antibody ge...

example 2

Topical Applications of Anti-IgE VHH's

[0384]To obtain anti-allergic pharmaceutical compositions for ophthalmic topical applications, a solution of anti-IgE VHH was prepared as follows:[0385]eye drops containing a therapeutic dose of anti-IgE VHH dissolved in 100 ml of sterilized water containing 0.9 g sodium chloride, 0.02 g sodium citrate, 0.02 g methyl parahydroxybenzoate, 0.1 g chlorobutanol and acetic acid suitable to obtain a pH of 6.5.[0386]eye ointment containing a therapeutic dose of anti-IgE VHH was prepared according to the conventional method containing 1.0 g of liquid paraffin and a suitable amount of soft paraffin to obtain a total mixture of 100 g.

example 3

Anti-IgE Formulation

[0387]Anti-IgE VHH's that block binding of IgE to its high-affinity receptor are of potential therapeutic value in the treatment of allergy.

[0388]Highly purified VHH#2H11 was dialysed into formulation buffer, followed by addition of lyoprotectant at an isotonic concentration. Isotonic formulation was performed as follows: VHH#2H11 at 25 mg / ml was formulated in 5 mM histidine buffer at pH 6 with 500 moles of sugar per mole antibody. This formulation is reconstituted with BWFI (0.9% benzyl alcohol) at a volume which results in a 100 mg / ml of antibody in 20 mM histidine at pH 6 with an isotonic sugar concentration of 340 nM. The binding activity of the anti-IgE VHH in the isotonic formulations was measured in an IgE receptor inhibition assay. It was found that binding activity was essentially unchanged following storage at 4° C. for up to 3 months.

[0389]TNF-Alpha

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No.10 / 534,292, filed May 9, 2005, which is a national stage filing under 35 U.S.C. §371 of international application PCT / BE03 / 00190, filed Nov. 7, 2003, which was published under PCT Article 21(2) in English, which claims priority to international application PCT / EP03 / 06581, filed Jun. 23, 2003, and international application PCT / EP03 / 07313, filed Jul. 8, 2003, and also claims the benefit under 35 U.S.C. 119(e) of U.S. provisional application Ser. No. 60 / 425,073, filed Nov. 8, 2002, and U.S. provisional application Ser. No. 60 / 425,063, filed Nov. 8, 2002.BACKGROUND[0002]Polypeptide therapeutics and in particular antibody-based therapeutics have significant potential as drugs because they have exquisite specificity to their target and a low inherent toxicity. However, they have one important drawback: these are complex, large molecules and therefore relatively unstable, and they are sensitive to brea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/12A61K39/395A61K9/14A61P11/06A61P19/02A61P31/06A61P31/16A61P35/00A61P37/06C07K16/10C07K16/12C07K16/18C07K16/24C07K16/28C07K16/30C07K16/36C07K16/40C07K16/42C07K16/46C12N15/13G01N33/577
CPCA61K2039/505C07K2319/31C07K16/241C07K16/249C07K16/2863C07K16/2875C07K16/36C07K16/40C07K16/4291C07K2317/22C07K2317/24C07K2317/31C07K2317/565C07K2317/569C07K2317/62C07K2317/626C07K2317/76C07K2317/77C07K2319/00C07K16/18A61P1/00A61P1/04A61P1/14A61P1/16A61P3/10A61P5/00A61P7/00A61P7/02A61P7/06A61P9/08A61P9/10A61P11/00A61P11/06A61P13/00A61P13/12A61P15/08A61P17/02A61P17/06A61P19/02A61P21/04A61P25/00A61P25/02A61P27/02A61P27/16A61P29/00A61P31/06A61P31/16A61P35/00A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00C07K16/468
Inventor SILENCE, KARENVAECK, MARKVAN BERGEN EN HENEGOUWEN, PAUL M. P.
Owner ABLYNX NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com